A clinical safety study of Kerra formula capsules following oral administration in healthy volunteers
Pharmacy Practice
Abstract
Background: Kerra formula, derived from Tak-Ka-Si-La, an ancient Thai compilation, is composed of nine medicinal plants and used for its fever-reducing properties. It has been primarily employed to alleviate fever and was also used by some individuals in Thailand during COVID-19 infections. Moreover, a previous in vitro study indicated the potential of the Kerra formula to inhibit SARS-CoV-2 main protease and RNA-dependent RNA polymerase (RdRp). This study aimed to assess the safety and short-term side effects of Kerra formula capsules on 11 healthy volunteers. Methods: Two capsules of 500 mg were taken orally 4 times daily for 2 weeks. Symptoms, medical history, physical examination, and laboratory tests were examined. Parameters assessed included complete blood count, coagulation profiles, liver and renal function tests, urinalysis, inflammation markers, fasting blood sugar, and lipid profiles. Results: Comparing baseline and post-capsule results at 1, 7, and 14 days, and after a 14-day washout period, no abnormalities were found in physical examination. Moreover, no adverse reactions or statistically significant differences occurred in laboratory results. Additionally, favorable trends in blood pressure and lipid profiles suggest potential cardiovascular benefits. Conclusion: The study concludes that this protocol resulted in no deleterious effect in all volunteers, suggesting safe administration. However, further research is crucial to assess the herb’s long-term effects. In particular, its potential role in preventing or mitigating COVID-19 infection should be investigated for safety through studies in animal models, followed by clinical research in infected individuals to establish therapeutic relevance and elucidate mechanisms of action.
Keywords
- Kerra formula
- Ancient Thai compilation
- Safety Assessment
- Oral Administration
- Healthy Volunteers